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Examine the incremental cost-effectiveness of a 
multimarker assay, compared to the current high-
sensitive troponin assay, in excluding NSTEMI in 
patients with acute chest pain. 
o Multimarker: combined measurement of myelo-
peroxidase, copeptin, and high-sensitive troponin. 
 
o Questionnaire among 10 cardiologists. 
• Focus: influence of multimarker on patient’s 
discharge and diagnostic activities performed. 
 
Evaluation of: 
o A range of sensitivities and negative predictive 
values (NPVs) of the multimarker. 
• Based on literature analysis. 
 
o Three implementation strategies: 
I. Multimarker assay at the time of a patient’s 
entrance at the hospital (t0). 
II. Multimarker plus one troponin measurement 
after two hours (t2). 
III. Multimarker plus troponin measurements 
after two and six hours (t2 and t6). 
 
 
o Increased analytical performance by multimarker4. 
o Therefore, we recommend implementation of the 
multimarker with troponin assays at t2 and t6. 
o Further research is necessary. 
• Specify patients in categories (low, intermediate 
and high risk of myocardial infarction). 
• Development should focus on point-of care tests. 
 
o A large proportion of all emergency hospital 
admissions are due to chest pain1. 
• Majority of these patients do not have an acute 
myocardial infarction. 
o ECG is insufficient to exclude non ST-elevation 
myocardial infarction (NSTEMI)2. 
o Therefore: laboratory markers are crucial to 
achieve early  exclusion of NSTEMI. 
• Consequences: 
 Earlier patient discharge 
 Possible cost savings3.  
 
o Early economic evaluation, therefore: 
• Relatively much uncertainty in input variables.  
• Interpret results cautiously. 
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Troponin:  
sens. 85%, NPV 95% 
 
Multimarker: 
sens. 90%, NPV 96% 
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